cytomegaloviru
cmv
common
pathogen
caus
syndrom
rang
asymptomat
viremia
endorgan
diseas
cmv
infect
result
high
morbid
mortal
rate
especi
immunocompromis
patient
cellmedi
immunodefici
incid
cmv
pneumonia
patient
diagnos
hematolog
malign
report
rang
overal
mortal
rate
increas
literatur
describ
nontranspl
patient
risk
cmv
pneumonia
chronic
lymphocyt
leukemia
lymphoma
use
rituximab
system
steroid
alemtuzumab
busulfan
develop
immunosuppress
agent
increas
use
cmv
polymeras
chain
reaction
pcr
bronchoalveolar
lavag
bal
fluid
serum
would
increas
incid
cmv
pneumonia
nontranspl
patient
hematolog
malign
howev
diagnost
method
cmv
pneumonia
undergon
mark
develop
past
decad
definit
diagnosi
cmv
pneumonia
determin
base
combin
symptom
sign
pulmonari
diseas
detect
cmv
bal
fluid
lung
tissu
sampl
viru
isol
histopatholog
test
immunohistochem
analysi
situ
hybrid
pcr
use
detect
cmv
sinc
earli
sensit
method
detect
cmv
quantit
realtim
pcr
qrtpcr
use
quantifi
viral
load
blood
bal
fluid
viral
load
blood
good
predictor
cmv
diseas
use
preemptiv
therapi
bone
marrow
transplant
bmt
howev
viral
load
bal
fluid
determin
qrtpcr
low
specif
posit
predict
valu
despit
high
sensit
neg
predict
valu
moreov
asymptomat
lung
viral
infect
report
patient
hematolog
malign
immunocompet
host
without
evid
acut
cmv
diseas
thu
remain
difficult
distinguish
cmv
infect
cmv
endorgan
diseas
question
whether
viral
titer
higher
patient
cmv
pneumonia
exhibit
asymptomat
pulmonari
shed
remain
controversi
method
measur
cmv
dna
viral
load
standard
viral
cutoff
valu
distinguish
cmv
infect
cmv
pneumonia
establish
far
awar
defin
viral
cutoff
valu
sampl
whole
blood
diagnos
cmv
diseas
patient
hematolog
malign
cmv
dnaemia
could
diagnos
cmv
realtim
pcr
lung
transplant
recipi
cmv
cultur
bal
fluid
sensit
less
use
compar
histolog
assess
transbronchi
biopsi
regard
clinic
util
cmv
load
bal
fluid
one
clinic
studi
report
copiesml
mean
copiesml
sensit
specif
compar
posit
lung
biopsi
use
quantit
hybrid
captur
assay
howev
report
studi
aim
identifi
cmv
qrtpcr
cutoff
valu
bal
fluid
lack
studi
aim
evalu
diagnosi
cmv
pneumonia
patient
hematolog
malign
use
cmv
qrtpcr
defin
viral
load
cutoff
valu
enabl
discrimin
cmv
pneumonia
cmv
infect
use
bronchial
wash
fluid
specimen
identifi
adult
patient
year
age
hematolog
malign
underw
bronchoscopi
isol
caus
pathogen
pneumonia
march
june
seoul
st
mari
hospit
seoul
republ
korea
bmt
perform
annual
clinic
diagnost
criteria
pneumonia
includ
new
infiltr
chest
radiograph
clinic
sign
lower
respiratori
tract
infect
andor
fever
microbiolog
find
bronchial
wash
fluid
patient
analyz
retrospect
addit
assay
blood
cmv
qrtpcr
lung
biopsi
also
review
data
regard
follow
clinic
characterist
patient
collect
age
sex
hematolog
diagnosi
prior
hematolog
treatment
transplant
characterist
studi
approv
institut
review
board
seoul
st
mari
hospit
waiv
requir
inform
consent
bronchoscopi
perform
identif
pulmonari
infiltr
chest
comput
tomographi
ct
bronchoscop
examin
perform
use
flexibl
bronchoscop
olympu
tokyo
japan
experienc
bronchoscopist
bronchial
wash
conduct
bronchoscop
wedg
segment
bronchu
consist
newli
develop
infiltr
detect
chest
ct
ml
normal
salin
repeatedli
instil
least
ml
aspir
collect
trap
bottl
direct
examin
cultur
bacteria
fungi
virus
perform
bronchoscop
wash
fluid
specimen
detect
bacteria
mycobacteria
fungi
gram
periodicacid
schiff
gomori
methenamin
silver
stain
analys
tissu
perform
follow
cultur
detect
respiratori
virus
multiplex
qpcr
assay
perform
influenza
virus
b
parainfluenza
virus
respiratori
syncyti
viru
adenoviru
metapneumoviru
rhinoviru
b
c
coronaviru
bocaviru
advansur
rv
realtim
pcr
kit
lg
life
scienc
seoul
korea
polymeras
chain
reaction
assay
also
use
detect
pneumocysti
jirovecii
mycobacteria
cmv
detect
qrtpcr
cmv
dna
shell
vial
cultur
immunohistochem
ihc
stain
cmv
bronchial
wash
fluid
moreov
ihc
stain
cmv
transbronchi
lung
biopsi
review
experienc
lung
pathologist
qrtpcr
cmv
dna
extract
whole
blood
bronchial
wash
fluid
use
qiaamp
dna
blood
kit
qiagen
valencia
ca
usa
accord
manufactur
instruct
rtpcr
cmv
dna
perform
use
instrument
bioneer
corpor
daejeon
korea
cmv
quantit
pcr
kit
bioneer
establish
limit
detect
lod
amplifi
control
sampl
copiesml
twice
daili
day
two
set
total
sampl
perform
probit
analysi
lod
copiesml
standard
result
world
health
organ
intern
standard
human
cmv
nucleic
acid
amplif
techniqu
nation
institut
biolog
standard
control
nibsc
code
use
intern
standard
dilut
iuml
replic
concentr
run
separ
day
data
collect
copiesml
compar
expect
iuml
convers
factor
calcul
take
mean
ratio
iuml
copiesml
data
point
one
copi
cmv
dna
use
cmv
quantit
pcr
test
equival
intern
unit
iu
cmv
pneumonia
suspect
patient
present
sign
symptom
pneumonia
chest
ct
find
compat
viral
pneumonia
cmv
pneumonia
defin
accord
establish
criteria
cmv
diagnosi
categor
proven
probabl
possibl
indetermin
experienc
specialist
lee
dg
divis
infecti
diseas
accord
retrospect
review
individu
chart
chest
ct
find
tabl
patient
copathogen
aspergillu
spp
detect
bronchial
wash
fluid
radiolog
sign
typic
invas
pulmonari
aspergillosi
ipa
exclud
statist
analys
perform
use
spss
softwar
ver
window
spss
inc
chicago
il
usa
result
express
mean
sem
continu
variabl
proport
categor
variabl
cmv
qrtpcr
result
present
mean
median
rang
differ
cmv
pcr
titer
patient
diagnos
without
cmv
pneumonia
analyz
use
utest
test
twosid
p
valu
consid
indic
statist
signific
identifi
optim
viral
load
cutoff
valu
differenti
patient
diagnos
cmv
pneumonia
cmv
infect
oper
characterist
sensit
specif
calcul
cutoff
valu
receiv
oper
characterist
roc
curv
plot
determin
accur
cutoff
point
bronchoscopi
perform
mean
day
identif
new
pulmonari
infiltr
suggest
pneumonia
among
initi
identifi
patient
neg
cmv
exhibit
copiesml
iuml
cmv
dna
qrtpcr
harbor
copiesml
accord
consensu
criteria
patient
diagnos
cmv
pneumonia
exhibit
find
inconsist
cmv
pneumonia
exclud
due
suspicion
proven
ipa
patient
diagnos
cmv
pneumonia
classifi
proven
cmv
pneumonia
possibl
probabl
indetermin
figur
supplementari
figur
nine
case
classifi
proven
base
posit
cmv
cultur
bronchial
wash
fluid
five
lung
biopsi
specimen
two
indetermin
case
classifi
coinfect
respiratori
virus
coronaviru
rhinoviru
baselin
characterist
patient
prior
treatment
shown
tabl
mean
age
year
patient
male
common
underli
hematolog
diseas
acut
myeloid
leukemia
hemophagocyt
lymphohistiocytosi
nonhodgkin
lymphoma
aplast
anemia
sixteen
patient
use
immunosuppress
agent
time
diagnosi
cmv
pneumonia
receiv
system
alemtuzumab
steroid
puls
therapi
methylprednisolon
mgkgday
aggrav
gvhd
last
day
patient
diagnos
cmv
pneumonia
treat
antivir
agent
result
aggrav
pneumonia
improv
patient
mean
day
follow
patient
die
mortal
rate
death
due
cmv
pneumonia
patient
among
total
patient
patient
coinfect
seven
patient
coinfect
bacteria
staphylococcu
aureu
pseudomona
aeruginosa
stenophomona
maltophilia
mycoplasma
virus
coronaviru
parainfluenza
viru
rhinoviru
fungi
pneumocysti
jirovecii
aspergillu
niger
mycobacterium
speci
mycobacterium
tuberculosi
nontubercul
mycobacterium
tabl
show
transplant
characterist
patient
diagnos
cmv
pneumonia
diagnos
patient
undergon
bmt
mean
time
diagnosi
cmv
pneumonia
bmt
day
howev
major
patient
diagnos
day
bmt
four
patient
histori
preemptiv
cmv
therapi
time
undergo
bmt
diagnosi
cmv
pneumonia
patient
cmv
pneumonia
diagnos
late
period
day
rang
day
data
shown
bmt
frequent
donor
sibl
two
patient
undergon
autotransplant
figur
show
distribut
cmv
qrtpcr
viral
load
bronchial
wash
fluid
median
cmv
qrtpcr
copiesml
valu
rang
patient
diagnos
cmv
pneumonia
rang
diagnos
cmv
pneumonia
differ
signific
p
tabl
show
qrtpcr
result
patient
n
versu
without
diagnosi
cmv
pneumonia
n
median
cmv
load
bronchial
wash
fluid
significantli
differ
two
group
vs
without
cmv
pneumonia
copiesml
vs
copiesml
utest
p
median
cmv
load
blood
also
significantli
differ
two
group
copiesml
vs
copiesml
respect
utest
p
patient
diagnos
cmv
pneumonia
sixfold
higher
median
blood
cmv
load
diagnos
cmv
pneumonia
receiv
oper
characterist
roc
curv
plot
identifi
optim
cutoff
valu
cmv
load
bronchial
wash
fluid
diagnosi
cmv
pneumonia
among
patient
analyz
nobmt
statu
postbmt
statu
sixteen
postbmt
patient
diagnos
cmv
pneumonia
supplementari
figur
roc
curv
show
optim
inflect
point
postbmt
patient
copiesml
iuml
auc
p
sensit
specif
figur
among
nobmt
patient
cmv
pneumonia
viral
cutoff
level
copiesml
iuml
auc
p
sensit
specif
figur
base
qrtpcr
result
patient
diagnos
versu
diagnos
cmv
pneumonia
cmv
load
copiesml
n
area
curv
auc
valu
confid
interv
ci
p
optim
inflect
point
copiesml
iuml
sensit
specif
figur
studi
demonstr
cmv
load
bronchial
wash
fluid
determin
qrtpcr
could
indic
lung
involv
cmv
diseas
patient
diagnos
cmv
pneumonia
significantli
higher
qrtpcr
cmv
titer
find
inconsist
cmv
pneumonia
bronchial
wash
fluid
higher
whole
blood
higher
moreov
use
roc
curv
cutoff
valu
copiesml
sensit
specif
cmv
dna
bronchial
wash
fluid
correl
cmv
pneumonia
preval
cmv
pneumonia
bmt
center
posit
neg
predict
valu
respect
data
valuabl
first
time
provid
optim
cut
point
cmv
dna
patient
hematolog
malign
result
help
clinician
diagnos
cmv
pneumonia
easili
patient
hematolog
malign
although
patholog
confirm
gold
standard
diagnosi
lung
biopsi
usual
carri
high
risk
bleed
patient
hematolog
malign
data
suggest
noninvas
bronchial
wash
procedur
may
replac
invas
lung
biopsi
diagnosi
cmv
pneumonia
patient
also
cut
point
cmv
qrtpcr
could
supplementari
inform
earli
detect
cmv
pulmonari
infiltr
patient
hematolog
malign
detect
cmv
bal
fluid
pcr
bmt
recipi
evalu
cathoma
et
al
report
among
patient
cmv
pneumonia
cmv
infect
without
pneumonia
pcr
assay
show
sensit
rel
low
specif
posit
predict
valu
compens
addit
perform
cmv
immunostain
result
posit
predict
valu
specif
hohenth
et
al
report
among
bal
fluid
sampl
patient
hematolog
malign
diagnos
pneumonia
cmv
pcr
posit
obtain
patient
definit
probabl
cmv
pneumonia
howev
signific
posit
pcr
find
unknown
patient
sinc
studi
feasibl
cmv
detect
pcr
use
bal
fluid
patient
diagnos
hematolog
malign
report
lung
transplant
recipi
chemali
et
al
describ
viral
cutoff
bal
fluid
copiesml
viral
cutoff
quit
differ
howev
assum
discrep
could
driven
differ
host
immun
statu
much
smaller
studi
popul
chemali
studi
furthermor
knowledg
studi
evalu
use
qpcr
method
discrimin
cmv
pneumonia
cmv
infect
studi
uniqu
term
use
qrtpcr
enabl
quantit
comparison
inclus
consider
larger
popul
previou
work
bal
standard
method
use
detect
viral
pathogen
pneumonia
patient
hematolog
malign
bmt
center
perform
bronchial
wash
wedg
bronchoscop
one
select
segment
bronchu
identifi
pathogen
present
pulmonari
infiltr
minim
alveolar
damag
incid
cmv
pneumonia
studi
well
correspond
previou
report
simplifi
bronchial
wash
procedur
bal
studi
sever
limit
first
patient
cmv
infect
proven
lung
biopsi
cultur
includ
roc
curv
analysi
clinic
diagnosi
cmv
pneumonia
debat
experienc
specialist
exclud
patient
etiolog
infect
noninfecti
condit
analysi
mean
strict
review
result
patient
treat
anticmv
agent
andor
cmv
immunoglobulin
none
improv
spontan
without
antivir
agent
also
percentag
diagnos
specimen
among
studi
sampl
rang
valu
report
cathoma
hohenth
second
among
diagnos
patient
undergon
bmt
prior
diagnosi
cmv
pneumonia
center
conduct
riskadapt
preemptiv
therapi
bmt
sinc
accord
bmt
type
gvhd
grade
four
patient
diagnos
cmv
pneumonia
histori
preemptiv
therapi
bmt
sinc
strategi
prevent
cmv
pneumonia
diagnosi
nonbmt
patient
hematolog
malign
remain
determin
none
eight
nonbmt
patient
histori
preemptiv
therapi
cmv
diseas
separ
analyz
roc
curv
cmv
titer
refer
bmt
statu
viral
cutoff
copiesml
iuml
postbmt
patient
copiesml
iuml
nobmt
patient
viral
cutoff
nobmt
patient
much
higher
postbmt
patient
differ
clinic
relev
due
longterm
immun
suppress
requir
postbmt
transfer
viru
seroposit
donor
whether
patient
underw
bmt
influenc
risk
cmv
reactiv
endorgan
diseas
found
exclus
nobmt
patient
made
littl
differ
determin
cutoff
level
decreas
copiesml
iuml
copiesml
iuml
howev
postbmt
patient
diagnos
cmv
pneumonia
present
studi
small
number
may
compromis
accuraci
roc
curv
cmv
titer
determin
qrtpcr
analyz
accord
bmt
statu
risk
cmv
diseas
larger
popul
obtain
statist
signific
data
moreov
cutoff
level
valid
prospect
deriv
time
appli
dataset
third
pulmonari
hemorrhag
may
play
viral
load
bal
may
reflect
cmv
reactiv
blood
identifi
patient
pulmonari
alveolar
hemorrhag
among
diagnos
cmv
pneumonia
case
hemorrhag
among
patient
diagnos
cmv
pneumonia
roc
curv
drawn
exclus
patient
possibl
pulmonari
hemorrhag
viral
cutoff
valu
copiesml
iuml
auc
ci
p
sensit
specif
thu
exclus
patient
pulmonari
hemorrhag
creat
minim
interv
chang
cutoff
valu
possibl
blood
cmv
titer
low
patient
data
shown
lastli
also
review
effect
antivir
treatment
prior
bronchoscopi
two
patient
identifi
preemptiv
treat
ganciclovir
suspicion
cmv
reactiv
upon
examin
blood
cmv
pcr
titer
howev
interv
commenc
antivir
agent
bronchoscopi
rel
short
day
effect
would
expect
minim
cmv
load
bronchial
wash
fluid
whole
blood
determin
qpcr
could
indic
lung
involv
cmv
diseas
cutoff
valu
copiesml
iuml
cmv
dna
bronchial
wash
fluid
correl
cmv
pneumonia
